Ladenburg analyst Kevin Degeeter initiated coverage of Cardiff Oncology (CRDF) with a Buy rating and $19 price target The firm, which sees potential for onvansertib to become a new treatment option for first-line KRAS and NRAS mutated colorectal cancer, expects a planned update on July 29 to clarify the tolerability profile and potentially enable selection of an onvansertib dose for Phase 3 development.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Cardiff Oncology Holds Annual Stockholders Meeting 2025
- Cardiff Oncology initiated with a Hold at Jefferies
- Cardiff Oncology to share CRDF-004 trial data on July 29
- Cardiff selloff brings attractive entry point, says H.C. Wainwright
- Strategic Delay and Promising Trial Results Position Cardiff Oncology for Growth in KRAS+ Colorectal Cancer Market